Clinical Trial Update: A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium [Phase 2]

View source ↗

Summary

This update describes the completed Phase 2 trial of pemetrexed (ALIMTA) in locally advanced or metastatic urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urologic Neoplasms, Metastases, Neoplasm | Phase 2 | Status: COMPLETED